287 related articles for article (PubMed ID: 34725358)
21. TcdB of
Stieglitz F; Gerhard R; Hönig R; Giehl K; Pich A
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457076
[TBL] [Abstract][Full Text] [Related]
22. On the Potential Significance of the Intrinsically Disordered Regions in the Clostridiodes difficile Toxins A and B.
El Hadidy N; Uversky VN; Sun X
Curr Protein Pept Sci; 2022 Jul; 23(3):192-209. PubMed ID: 35585826
[TBL] [Abstract][Full Text] [Related]
23. Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B.
Simeon R; Jiang M; Chamoun-Emanuelli AM; Yu H; Zhang Y; Meng R; Peng Z; Jakana J; Zhang J; Feng H; Chen Z
PLoS Biol; 2019 Jun; 17(6):e3000311. PubMed ID: 31233493
[TBL] [Abstract][Full Text] [Related]
24. A neutralizing antibody that blocks delivery of the enzymatic cargo of
Kroh HK; Chandrasekaran R; Zhang Z; Rosenthal K; Woods R; Jin X; Nyborg AC; Rainey GJ; Warrener P; Melnyk RA; Spiller BW; Lacy DB
J Biol Chem; 2018 Jan; 293(3):941-952. PubMed ID: 29180448
[No Abstract] [Full Text] [Related]
25. Clostridial toxins: sensing a target in a hostile gut environment.
Oezguen N; Power TD; Urvil P; Feng H; Pothoulakis C; Stamler JS; Braun W; Savidge TC
Gut Microbes; 2012; 3(1):35-41. PubMed ID: 22356854
[TBL] [Abstract][Full Text] [Related]
26. Clinical and microbiologic characteristics of tcdA-negative variant Clostridium difficile infections.
Kim J; Pai H; Seo MR; Kang JO
BMC Infect Dis; 2012 May; 12():109. PubMed ID: 22571633
[TBL] [Abstract][Full Text] [Related]
27. Functional properties of the carboxy-terminal host cell-binding domains of the two toxins, TcdA and TcdB, expressed by Clostridium difficile.
Dingle T; Wee S; Mulvey GL; Greco A; Kitova EN; Sun J; Lin S; Klassen JS; Palcic MM; Ng KK; Armstrong GD
Glycobiology; 2008 Sep; 18(9):698-706. PubMed ID: 18509107
[TBL] [Abstract][Full Text] [Related]
28. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.
Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP
Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518
[TBL] [Abstract][Full Text] [Related]
29. Intrinsic Toxin-Derived Peptides Destabilize and Inactivate
Larabee JL; Bland SJ; Hunt JJ; Ballard JD
mBio; 2017 May; 8(3):. PubMed ID: 28512094
[No Abstract] [Full Text] [Related]
30. The enterotoxicity of Clostridium difficile toxins.
Sun X; Savidge T; Feng H
Toxins (Basel); 2010 Jul; 2(7):1848-80. PubMed ID: 22069662
[TBL] [Abstract][Full Text] [Related]
31. Functional defects in
Gupta P; Zhang Z; Sugiman-Marangos SN; Tam J; Raman S; Julien JP; Kroh HK; Lacy DB; Murgolo N; Bekkari K; Therien AG; Hernandez LD; Melnyk RA
J Biol Chem; 2017 Oct; 292(42):17290-17301. PubMed ID: 28842504
[No Abstract] [Full Text] [Related]
32. Rational design of inhibitors and activity-based probes targeting Clostridium difficile virulence factor TcdB.
Puri AW; Lupardus PJ; Deu E; Albrow VE; Garcia KC; Bogyo M; Shen A
Chem Biol; 2010 Nov; 17(11):1201-11. PubMed ID: 21095570
[TBL] [Abstract][Full Text] [Related]
33. Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo.
Kordus SL; Kroh HK; Rodríguez RC; Shrem RA; Peritore-Galve FC; Shupe JA; Wadzinski BE; Lacy DB; Spiller BW
PLoS Pathog; 2023 Oct; 19(10):e1011496. PubMed ID: 37871122
[TBL] [Abstract][Full Text] [Related]
34. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.
Hirota SA; Iablokov V; Tulk SE; Schenck LP; Becker H; Nguyen J; Al Bashir S; Dingle TC; Laing A; Liu J; Li Y; Bolstad J; Mulvey GL; Armstrong GD; MacNaughton WK; Muruve DA; MacDonald JA; Beck PL
Infect Immun; 2012 Dec; 80(12):4474-84. PubMed ID: 23045481
[TBL] [Abstract][Full Text] [Related]
35. The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model.
Zhang Y; Yang Z; Gao S; Hamza T; Yfantis HG; Lipsky M; Feng H
Anaerobe; 2017 Dec; 48():249-256. PubMed ID: 29031928
[TBL] [Abstract][Full Text] [Related]
36. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production.
Merrigan M; Venugopal A; Mallozzi M; Roxas B; Viswanathan VK; Johnson S; Gerding DN; Vedantam G
J Bacteriol; 2010 Oct; 192(19):4904-11. PubMed ID: 20675495
[TBL] [Abstract][Full Text] [Related]
37. Clostridium difficile Toxin A Undergoes Clathrin-Independent, PACSIN2-Dependent Endocytosis.
Chandrasekaran R; Kenworthy AK; Lacy DB
PLoS Pathog; 2016 Dec; 12(12):e1006070. PubMed ID: 27942025
[TBL] [Abstract][Full Text] [Related]
38. Plakoglobin and High-Mobility Group Box 1 Mediate Intestinal Epithelial Cell Apoptosis Induced by Clostridioides difficile TcdB.
Li Y; Xu W; Ren Y; Cheung HC; Huang P; Kaur G; Kuo CJ; McDonough SP; Fubini SL; Lipkin SM; Deng X; Chang YF; Huang L
mBio; 2022 Oct; 13(5):e0184922. PubMed ID: 36043787
[TBL] [Abstract][Full Text] [Related]
39. Adenosine receptors differentially mediate enteric glial cell death induced by
Costa DVS; Shin JH; Goldbeck SM; Bolick DT; Mesquita FS; Loureiro AV; Rodrigues-Jesus MJ; Brito GAC; Warren CA
Front Immunol; 2022; 13():956326. PubMed ID: 36726986
[TBL] [Abstract][Full Text] [Related]
40. The structure of Clostridium difficile toxin A glucosyltransferase domain bound to Mn2+ and UDP provides insights into glucosyltransferase activity and product release.
D'Urzo N; Malito E; Biancucci M; Bottomley MJ; Maione D; Scarselli M; Martinelli M
FEBS J; 2012 Sep; 279(17):3085-97. PubMed ID: 22747490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
